/. Automatiquement-calculés-cho, . Naa, and . Cho, Cr étaient disponibles pour 56% des patients (n=34) La moyenne des valeurs du ratio Cho/NAA dans le groupe P, pp.8358-91

. La-moyenne-des-valeurs-du and . Cho, Cr dans le groupe P était de 1,11 ± 0,33 (min : 0,68- max : 1,83) versus 1,13 ± 0, pp.3178-76

P. Bailey and H. Cushing, A classification of the tumors of the glioma group on a histogenetic basis with a correlated study of prognosis, 1926.

J. Kernohan and G. Sayre, Tumors of the central nervous system. Atlas of tumor pathology (fasc 35) Armed Forces Institute of Pathology, 1952.

K. Zülch, Types histologiques du système nerveux central, Genève: OMS, 1979.

P. Kleihues, P. Burger, and B. Scheithauer, Histological typing of tumours of the central nervous system.World Health Organization international histological classification of tumours, Heildelberg, 1993.

P. Kleihues and W. Cavenee, World Health Organization Classification of Tumours

L. Dn, The 2007 WHO classification of tumours of the central nervous system, Acta Neuropathol, pp.11-97, 2007.

H. Ohgaki and P. Kleihues, Epidemiology and etiology of gliomas, Acta Neuropathologica, vol.43, issue.1, 2005.
DOI : 10.1007/s00401-005-0991-y

Q. Ostrom, H. Gittleman, L. Stetson, S. Virk, and J. Barnholtz-sloan, Epidemiology of Gliomas, Cancer Treat Res, vol.163, pp.1-14, 2015.
DOI : 10.1007/978-3-319-12048-5_1

H. Ohgaki, A population-based study of the incidence and survival rates in patients with astrocytic pilocytoma, J Neurosurg, vol.98, issue.6, pp.1170-1174, 2003.

L. Morgan, The epidemiology of glioma in adults: a "state of the science" review, Neuro-Oncology, vol.17, issue.4
DOI : 10.1093/neuonc/nou358

S. Sathornsumetee, J. Rich, and D. Reardon, Diagnosis and Treatment of High-Grade Astrocytoma, Neurologic Clinics, vol.25, issue.4, pp.1111-1150, 2007.
DOI : 10.1016/j.ncl.2007.07.004

. Oligodendrogliomas, II: a new grading system based on morphological and imaging criteria, J Neurooncol, vol.34, pp.61-78, 1997.

A. Inbaih, A. Duran-pena, C. Bonnet, and F. Ducray, Input of molecular analysis in medical management of primary brain tumor patients, Rev Neurol, vol.171, pp.6-7457, 2015.

S. Taillebert and L. Rhun, Epidemiology of brain metastases. Cancer Radiother, 2015.

S. Grand, C. Pasteris, A. Attye, L. Bas, J. Krainik et al., Les diff??rents visages des m??tastases du syst??me nerveux central, Journal de Radiologie Diagnostique et Interventionnelle, vol.95, issue.10, pp.908-930, 2014.
DOI : 10.1016/j.jradio.2014.05.007

J. Delarive, N. De-tribolet, A. Kallel, O. Bailon, and A. Carpentier, Cerebral metastases. A study of a surgical series of 81 casesClinical symptoms and symptomatic management of brain metastases, Neurochirurgie Bull Cancer, vol.38, issue.984, pp.89-97371, 1992.

M. Forsting, F. Albert, S. Kunze, H. Adams, D. Zenner et al., Extirpation of glioblastomas : MR and CT follow-up of residual tumor and regrowth patterns, AJNR Am J Neuroradiol, vol.14, issue.1, pp.77-87, 1993.

J. Perry, A. Chambers, K. Spithoff, and N. Laperriere, Gliadel?? Wafers in the Treatment of Malignant Glioma: A Systematic Review, Current Oncology, vol.14, issue.5, pp.189-94, 2007.
DOI : 10.3747/co.2007.147

M. Hart, R. Grant, R. Rogers, G. Somerville, M. Stein et al., Chemotherapy wafers for high grade glioma.Cochrane Database Syst Rev, 2011.

F. Calenbergh, R. Sciot, S. Van-gool, O. Bechter, P. Demaerel et al., Defining pseudoprogression in glioblastoma multiforme, Eur J Neurol, vol.20, issue.10, pp.1335-1376, 2013.

K. Knudsen-baas, G. Moen, Ø. Fluge, and A. Storstein, Pseudoprogression in high-grade glioma, Acta Neurologica Scandinavica, vol.94, issue.196, pp.31-38, 2013.
DOI : 10.1111/ane.12047

J. Fink, D. Born, and M. Chamberlain, Pseudoprogression: Relevance With Respect to Treatment of High-Grade Gliomas, Current Treatment Options in Oncology, vol.22, issue.6, pp.240-52, 2011.
DOI : 10.1007/s11864-011-0157-1

D. Brandsma, L. Stalpers, W. Taal, P. Sminia, and M. Van-den-bent, Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas, The Lancet Oncology, vol.9, issue.5, pp.453-61, 2008.
DOI : 10.1016/S1470-2045(08)70125-6

A. Fabi, M. Russillo, G. Metro, A. Vidiri, D. Giovanni et al., Pseudoprogression and MGMT status in glioblastoma patients : implications in clinical practice, Anticancer Res, vol.29, issue.7, pp.2607-2617, 2009.

A. Brandes, E. Franceschi, A. Tosoni, V. Blatt, A. Pession et al., Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients, Journal of Clinical Oncology, vol.26, issue.13, pp.2192-7387, 2008.
DOI : 10.1200/JCO.2007.14.8163

A. Ghiaseddin and K. Peters, Use of bevacizumab in recurrent glioblastoma, CNS Oncology, vol.4, issue.3
DOI : 10.2217/cns.15.8

E. Wong, S. Gautam, C. Malchow, M. Lun, E. Pan et al., Bevazicumab for recurrent glioblastoma multiforme : a meta-analysis, J Natl Compr Canc Netw. 2011, vol.9, issue.4, pp.403-410

G. Al-shamy and R. Sawaya, Management of brain metastases: the indispensable role of surgery, Journal of Neuro-Oncology, vol.51, issue.3, pp.275-82, 2009.
DOI : 10.1007/s11060-009-9839-y

J. Guillamo, E. Emery, A. Busson, E. Lechapt-zalcman, J. Constans et al., Current management of brain metastases, Rev Neurol, vol.164, pp.6-7560, 2008.

F. Bertolini, A. Spallanzani, A. Fontana, R. Depenni, and G. Luppi, Brain metastases: an overview, CNS Oncology, vol.4, issue.1, pp.37-46, 2015.
DOI : 10.2217/cns.14.51

F. Dhermain, N. Reyns, C. P. Metellus, P. Mornex, F. Noel et al., Radioth??rapie en conditions st??r??otaxiques des m??tastases c??r??brales, Cancer/Radioth??rapie, vol.19, issue.1, pp.25-34, 2015.
DOI : 10.1016/j.canrad.2014.12.002

C. Kim, Y. Im, D. Nam, K. Park, J. Kim et al., Gamma Knife Radiosurgery for Ten or More Brain Metastases, Journal of Korean Neurosurgical Society, vol.44, issue.6, pp.358-363, 2008.
DOI : 10.3340/jkns.2008.44.6.358

J. Flickinger and L. Lunsford, Stereotactic radiosurgery using the Leksell Gamma Knife Perfexion unit in the management of patients with 10 or more brain metastases, J Neurosurg, vol.117, pp.237-245, 2012.

A. K. Bindal, R. K. Bindal, and K. R. Hess, Surgery versus radiosurgery in the treatment of brain metastasis, Journal of Neurosurgery, vol.84, issue.5, pp.748-54, 1996.
DOI : 10.3171/jns.1996.84.5.0748

K. Parvez, A. Parvez, G. Zadeh, A. Kumar, N. Leeds et al., The Diagnosis and Treatment of Pseudoprogression, Radiation Necrosis and Brain Tumor Recurrence, International Journal of Molecular Sciences, vol.15, issue.7, pp.11832-46377, 1986.
DOI : 10.3390/ijms150711832

M. Husain and J. Garcia, Cerebral ?radiation necrosis?: Vascular and glial features, Acta Neuropathologica, vol.12, issue.4, pp.243-252, 1976.
DOI : 10.1007/BF00699643

Y. Yoshii, K. Sugimoto, and K. Fujiwara, Progressive enlargement of a mass lesion in late cerebral radionecrosis, Journal of Clinical Neuroscience, vol.18, issue.6, pp.853-858, 2011.
DOI : 10.1016/j.jocn.2010.08.041

J. Castel and J. Caille, Imaging of irradiated brain tumours: value of magnetic resonance imaging, J. Neuroradiol, vol.16, pp.81-132, 1989.

R. Sawaya, The fibrinolytic enzymes in the biology of brain tumors

S. Wong, K. Loo, K. Yam, W. Hung, K. Fok et al., Results of excision of cerebral radionecrosis: experience in patients treated with radiation therapy for nasopharyngeal carcinoma, Journal of Neurosurgery, vol.113, issue.2, pp.293-300, 2010.
DOI : 10.3171/2010.1.JNS091039

A. Lee, D. Kwong, S. Leung, S. Tung, W. Sze et al., Factors affecting risk of symptomatic temporal lobe necrosis: significance of fractional dose and treatment time, International Journal of Radiation Oncology*Biology*Physics, vol.53, issue.1, pp.75-85, 2002.
DOI : 10.1016/S0360-3016(02)02711-6

J. Ruben, M. Dally, M. Bailey, R. Smith, C. Mclean et al., Cerebral radiation necrosis: Incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy, International Journal of Radiation Oncology*Biology*Physics, vol.65, issue.2, pp.499-508, 2006.
DOI : 10.1016/j.ijrobp.2005.12.002

B. Blonigen, R. Steinmetz, L. Levin, M. Lamba, R. Warnick et al., Irradiated Volume as a Predictor of Brain Radionecrosis After Linear Accelerator Stereotactic Radiosurgery, International Journal of Radiation Oncology*Biology*Physics, vol.77, issue.4, pp.419-443, 2006.
DOI : 10.1016/j.ijrobp.2009.06.006

T. Korytko, T. Radivoyevitch, V. Colussi, B. Wessels, K. Pillai et al., 12 Gy gamma knife radiosurgical volume is a predictor for radiation necrosis in non-AVM intracranial tumors, International Journal of Radiation Oncology*Biology*Physics, vol.64, issue.2, pp.419-443, 2006.
DOI : 10.1016/j.ijrobp.2005.07.980

K. Leber, H. Eder, H. Kovac, U. Anegg, and G. Pendl, Treatment of Cerebral Radionecrosis by Hyperbaric Oxygen Therapy, Stereotactic and Functional Neurosurgery, vol.70, issue.1, pp.229-265, 1998.
DOI : 10.1159/000056426

J. Suh, Challenges with the diagnosis and treatment of cerebral radiation necrosis, Int J Radiat Oncol Biol Phys, vol.87, issue.3, pp.449-57, 2013.

R. Weichselbaum and M. Koshy, An analysis of radiation necrosis of the central nervous system treated with bevacizumab, J Neurooncol, vol.117, issue.2, pp.321-328, 2014.

S. Gronier, V. Bourg, M. Frenay, M. Cohen, L. Mondot et al., Le b??vacizumab dans le traitement des radion??croses c??r??brales, Revue Neurologique, vol.167, issue.4, pp.331-337, 2011.
DOI : 10.1016/j.neurol.2010.10.012

N. Nonoguchi, S. Miyatake, M. Fukumoto, M. Furuse, R. Hiramatsu et al., The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: pathological consideration of their potential roles, Journal of Neuro-Oncology, vol.16, issue.3, pp.423-454, 2011.
DOI : 10.1007/s11060-011-0610-9

R. Guillevin, C. Menuel, and J. Vallée, Multimodal magnetic resonance imaging of brain tumors, Rev Neurol, vol.167, issue.10, pp.70-74, 2011.

M. Molls, M. Weber, W. Mullins, M. Barest, G. Schaefer et al., Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis, Int J Radiat Oncol Biol Phys AJNR Am J Neuroradiol, vol.54, issue.268, pp.842-54, 2002.

K. Reddy, D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-grade gliomas, Journal of Medical Imaging and Radiation Oncology, vol.77, issue.3, pp.349-55, 2013.
DOI : 10.1111/j.1754-9485.2012.02472.x

J. Huang, A. Wang, A. Shetty, A. Maitz, D. Yan et al., Differentiation between intra-axial metastatic tumor progression and radiation injury following fractionated radiation 159
DOI : 10.1016/j.mri.2011.04.004

T. Patel, B. Mchugh, W. Bi, F. Minja, J. Knisely et al., A Comprehensive Review of MR Imaging Changes following Radiosurgery to 500 Brain Metastases, American Journal of Neuroradiology, vol.32, issue.10, pp.1885-92, 2011.
DOI : 10.3174/ajnr.A2668

I. Dequesada, R. Quisling, A. Yachnis, and W. Friedman, CAN STANDARD MAGNETIC RESONANCE IMAGING RELIABLY DISTINGUISH RECURRENT TUMOR FROM RADIATION NECROSIS AFTER RADIOSURGERY FOR BRAIN METASTASES? A RADIOGRAPHIC-PATHOLOGICAL STUDY, Neurosurgery, vol.63, issue.5, pp.898-904, 2008.
DOI : 10.1227/01.NEU.0000333263.31870.31

H. Kano, D. Kondziolka, J. Lobato-polo, O. Zorro, J. Flickinger et al., T1/T2 matching to differentiate tumor growth from radiation effects after stereotactic radiosurgery Extent of perilesional oedema differentiates radionecrosis from tumor recurrence following stereotactic radiosurgery for brain metastases, Neurosurgery Neuro Oncol, vol.66, issue.1512, pp.48691-711732, 2010.

D. Koh and D. Collins, Diffusion-Weighted MRI in the Body: Applications and Challenges in Oncology, American Journal of Roentgenology, vol.188, issue.6, pp.1622-1657, 2007.
DOI : 10.2214/AJR.06.1403

A. Raimbault, X. Cazals, M. Lauvin, C. Destrieux, S. Chapet et al., Radionecrosis of malignant glioma and cerebral metastasis: a diagnostic challenge in MRI. Diag Interv Imaging, pp.958-1000, 2014.

C. Asao, Y. Korogi, M. Kitajima, T. Hirai, Y. Baba et al., Diffusion-weighted imaging of radiation-induced brain injury for differentiation rom tumor recurrence, Am J Neuroradiol, vol.26, issue.6, pp.1455-60, 2005.

P. Hein, C. Eskey, J. Dunn, and E. Hug, Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury, AJNR Am J Neuroradiol, vol.25, issue.2, pp.201-210, 2004.

B. Bobek-billewicz, G. Stasik-pres, H. Majchrzak, and L. Zarudzki, Differentiation between brain tumor recurrence and radiation injury using perfusion, diffusion-weighted imaging and MR spectroscopy, Folia Neuropathol, vol.48, issue.2, pp.81-92, 2010.

Y. Chan, D. Yeung, S. Leung, and P. Chan, Diffusion-Weighted Magnetic Resonance Imaging in Radiation-Induced Cerebral Necrosis, Journal of Computer Assisted Tomography, vol.27, issue.5, pp.674-80, 2003.
DOI : 10.1097/00004728-200309000-00003

C. Cuenod and D. Balvay, Perfusion and vascular permeability: basic concepts and measurement in DCE-CT and DCE-MRI. Diagn Interv Imaging, pp.1187-204, 2013.

B. Griffith and R. Jain, Perfusion Imaging in Neuro-Oncology, Magnetic Resonance Imaging Clinics of North America, vol.24, issue.4, pp.497-511, 2015.
DOI : 10.1016/j.mric.2016.07.004

S. Lacerda and M. Law, Magnetic resonance perfusion and permeability imaging in brain tumors. Neuroiamging Clin N Am, pp.527-57, 2009.

S. Grand, F. Tahon, A. Attye, V. Lefournier, L. Bas et al., Perfusion imaging in brain disease. Diagn Interv Imaging, pp.1241-57, 2013.

L. Bas, J. Grand, S. Krainik, A. Lefournier, V. Tropres et al., IRM de perfusion des tumeurs c??r??brales, Journal de Radiologie, vol.87, issue.6, pp.807-828, 2006.
DOI : 10.1016/S0221-0363(06)74089-6

P. Yeh, R. Debbins, J. Heiserman, and J. , Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptbility-weighted contrast-enhanced perfusion MR imaging measurements, AJNR Am J Neuroradiol, vol.30, issue.3, pp.552-560, 2009.

C. Nieder, N. Andratschke, R. Price, B. Rivera, K. Ang et al., Innovative prevention strategies for radiation necrosis of the central nervous system Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproductibility study, Anticancer Res Radiology, vol.22, issue.224, pp.1017-1023797, 2002.

R. Barajas, J. Chang, P. Sneed, . Segal-mrn, M. Mcdermott et al., Distinguishing Recurrent Intra-Axial Metastatic Tumor from Radiation Necrosis Following Gamma Knife Radiosurgery Using Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging, American Journal of Neuroradiology, vol.30, issue.2, pp.367-721078, 2007.
DOI : 10.3174/ajnr.A1362

S. Cha, S. Lu, and G. Johnson, Dynamic susceptibility contrast MR imaging: Correlation of signal intensity changes with cerebral blood volume measurements, Journal of Magnetic Resonance Imaging, vol.14, issue.2, pp.114-133, 2000.
DOI : 10.1002/(SICI)1522-2586(200002)11:2<114::AID-JMRI6>3.0.CO;2-S

L. Bars, E. Gondry-jouet, C. Deramond, H. , L. Gars et al., Idy-Peretti I. MR diffusion and perfusion imaging in clinical practice, J Neuroradiol, vol.27, issue.1, pp.39-51, 2000.

E. Paulson and K. Schmainda, Comparison of Dynamic Susceptibility-weighted Contrast-enhanced MR Methods: Recommendations for Measuring Relative Cerebral Blood Volume in Brain Tumors, Radiology, vol.249, issue.2, pp.601-614, 2008.
DOI : 10.1148/radiol.2492071659

S. Kitahara, S. Nakasu, K. Murata, K. Sho, R. Ito et al., Evaluation of treatment-induced cerebral white matter injury by using diffusion tensor MR imaging : initial experience DCE and DSC MR perfusion imaging in the differentiation of recurrent tumour from treatment-related changes in patients with glioma, AJNR Am J Neuroradiol Clin Radiol, vol.26, issue.696, pp.2200-2206, 2005.

S. Grand, I. Tropres, D. Hoffmann, A. Ziegler, L. Bas et al., Proton magnetic resonance spectroscopy (1H-MRS) for the diagnosis of brain tumors and the evaluation of treatment

A. Elias, R. Carlos, E. Smith, D. Frechtling, B. George et al., MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injurySerial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery, Acad Radiol. Am J Neuroradiol, vol.18, issue.22, pp.613-637, 2001.

M. Heesters, R. Kamman, E. Mooyaart, K. Go, R. Carlos et al., Localized proton spectroscopy of inoperable brain gliomas Response to radiation therapyDeveloping a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions, J Neurooncol AJR Am J Roentgenol, vol.17, issue.1922, pp.27-35, 1993.

D. Yeung, Y. Chan, S. Leung, P. Poon, and C. Pang, Detection of an intense resonance at

S. Herminghaus, U. Pilatus, and W. Moller-hartmann, Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors, NMR in Biomedicine, vol.16, issue.1
DOI : 10.1002/nbm.793

H. Schlemmer, P. Bachert, and K. Herfarth, Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy, AJNR Am J Neuroradiol, vol.22, pp.1316-1340, 2001.

P. Van-tassel, J. Bruner, and M. Maor, MR of toxic effects of accelerated fractionation radiation therapy and carboplatin chemotherapy for malignant gliomas, Am J Neuroradiol, vol.16, pp.715-726, 1995.

H. Zhang, L. Ma, C. Wu, and B. Xu, Performance of SPECT in the differential diagnosis of glioma recurrence from radiation necrosis, Journal of Clinical Neuroscience, vol.22, issue.2, pp.229-266, 2015.
DOI : 10.1016/j.jocn.2014.06.102

L. Jeune, F. Dubois, F. Blond, S. Steinling, and M. , Sestamibi technetium-99m brain single-photon emission computed tomography to identify recurrent glioma in adults: 201 studies, Journal of Neuro-Oncology, vol.75, issue.2, pp.177-83, 2006.
DOI : 10.1007/s11060-005-9018-8

B. Richard, J. Gaillard, and J. Devaux, Positron emission tomography in clinical oncology, Presse Med, pp.276-83, 2003.

G. Bonardel, S. Lecoules, M. Mantzarides, T. Carmoi, E. Gontier et al., Positron emission tomography in internal medicine, 2007.

O. Warburg, On the Origin of Cancer Cells, Science, vol.123, issue.3191, pp.75-83, 1956.
DOI : 10.1126/science.123.3191.309

F. Vaylet, M. J. Bonardel, G. , L. Floch, H. Rivière et al., Quelle place en oncologie thoracique pour la tomographie par ??mission de positons au 18FDG (TEP-FDG) en 2010???, Revue de Pneumologie Clinique, vol.66, issue.4, pp.221-259, 2010.
DOI : 10.1016/j.pneumo.2010.07.010

L. Horky, E. Hsiao, S. Weiss, J. Drappatz, and V. Gerbaudo, Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis, Journal of Neuro-Oncology, vol.35, issue.8, pp.137-183, 2011.
DOI : 10.1007/s11060-010-0365-8

D. Langleben and G. Segall, PET in differentiation of recurrent brain tumor from radiation injury, J Nucl Med, vol.41, issue.11, pp.1861-1868, 2000.

S. Chao, J. Suh, S. Raja, S. Lee, and G. Barnett, The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery, International Journal of Cancer, vol.36, issue.3, pp.191-198, 2001.
DOI : 10.1002/ijc.1016

J. Talbot, K. Kerrou, N. Gault, F. Gutman, D. Grahek et al., La TEP dans les tumeurs malignes c??r??brales, La Presse M??dicale, vol.35, issue.9, pp.1347-53, 2006.
DOI : 10.1016/S0755-4982(06)74818-7

I. Caroline and M. Rosenthal, Imaging modalities in high-grade gliomas: Pseudoprogression, recurrence, or necrosis?, Journal of Clinical Neuroscience, vol.19, issue.5, pp.633-640
DOI : 10.1016/j.jocn.2011.10.003

A. Patsouris, P. Augereau, J. Tanguy, O. Morel, P. Menei et al., Differential diagnosis of local tumor recurrence or radionecrosis after stereotactic radiosurgery for treatment of brain metastasis.Cancer Radiother, pp.142-148, 2014.

A. Glaudemans, R. Enting, M. Heesters, R. Dierckx, R. Van-rheenen et al., Value of 11C-methionine PET in imaging brain tumours and metastases, European Journal of Nuclear Medicine and Molecular Imaging, vol.40, issue.Suppl 3, pp.615-650, 2013.
DOI : 10.1007/s00259-012-2295-5

T. Singhal, T. Narayanan, V. Jain, J. Mukherjee, and J. Mantil, 11C-l-Methionine Positron Emission Tomography in the Clinical Management of Cerebral Gliomas, Molecular Imaging and Biology, vol.144, issue.1, pp.1-18
DOI : 10.1007/s11307-007-0115-2

I. Götz and A. Grosu, FET-PET imaging for Treatment and Response Monitoring of Radiation Therapy in Malignant Glioma Patients-A Review. Front Oncol, p.104, 2013.

W. Weber, H. Wester, A. Grosu, M. Herz, B. Dzewas et al., O -(2-[ 18 F]Fluoroethyl)- l -tyrosine and l -[methyl- 11 C]methionine uptake in brain tumours: initial results of a comparative study, European Journal of Nuclear Medicine and Molecular Imaging, vol.27, issue.5, pp.542-551, 2000.
DOI : 10.1007/s002590050541

G. Pöpperl, C. Götz, W. Rachinger, F. Gildehaus, J. Tonn et al., Value of O-(2-[18F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma, European Journal of Nuclear Medicine and Molecular Imaging, vol.29, issue.11, pp.1464-70, 2004.
DOI : 10.1007/s00259-004-1590-1

C. Giannesini, V. Izrael, M. Schlienger, and J. Talbot, Fluroethyltyrosine 18 F PET in the detection of brain tumours. Bull Cancer, pp.495-506, 2010.

M. Weinzierl, M. Stoffel, M. Sabel, G. Fink, N. Shah et al., The use of dynamic O-(2-18-F- fluoroethyl)-I-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma, Neuro Oncol, 201524.

W. Chen, D. Silverman, S. Delaloye, J. Czernin, N. Kamdar et al., 18 F-DOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy, J Nucl Med, vol.47, issue.6, pp.904-915, 2006.

A. Becherer, G. Karanikas, M. Szabo, G. Zettinig, S. Asenbaum et al., Brain tumour imaging with PET : a comparison between (18F] fluorodopa and [11C] methionine, Eur J Nucl Med Mol Imaging

K. Lizagarra, D. Salles, A. Chen, and W. , F-fluorodopa positron-emission tomography: an emerging imaging modality for patients with brain metastases, Expert Review of Medical Devices, vol.11, issue.4, pp.327-336
DOI : 10.1586/17434440.2014.925396

F. Cicone, G. Minniti, A. Romano, A. Papa, C. Scaringi et al., Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery, European Journal of Nuclear Medicine and Molecular Imaging, vol.66, issue.Suppl, pp.103-114
DOI : 10.1007/s00259-014-2886-4

S. Karunanithi, P. Sharma, A. Kumar, B. Khangembam, G. Bandopadhyaya et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent glioma, European Radiology, vol.31, issue.9, pp.2628-2663, 2013.
DOI : 10.1007/s00330-013-2838-6

H. Kim, M. Goh, N. Kim, C. Choi, S. Kim et al., Which Combination of MR Imaging Modalities Is Best for Predicting Recurrent Glioblastoma? Study of Diagnostic Accuracy and Reproducibility, Radiology, vol.273, issue.3, pp.831-874, 2014.
DOI : 10.1148/radiol.14132868

S. Blasel, A. Zagorcic, A. Jurcoane, O. Bähr, M. Wagner et al., Perfusion MRI in the Evaluation of Suspected Glioblastoma Recurrence, Journal of Neuroimaging, vol.33, issue.1, 2015.
DOI : 10.1111/jon.12247

J. Andre, S. Nagpal, D. Hippe, A. Ravanpay, H. Schmiedeskamp et al., Cerebral Blood Flow Changes in Glioblastoma Patients Undergoing Bevacizumab Treatment Are Seen in Both Tumor and Normal Brain, The Neuroradiology Journal, vol.162, issue.6, pp.112-121
DOI : 10.1007/978-1-4419-0318-1

P. Metellus, G. Dutertre, C. Mekkaoui, I. Nanni, S. Fuentes et al., Value of relative cerebral blood volume measurement using perfusion MRI in glioma management

S. Bisdas, T. Naegele, and R. Ritz, Distinguishing Recurrent High-grade Gliomas from Radiation Injury, Academic Radiology, vol.18, issue.5, pp.575-83, 2011.
DOI : 10.1016/j.acra.2011.01.018

H. Zhang, L. Ma, C. Shu, Y. Wang, and L. Dong, Diagnostic accuracy of diffusion MRI with quantitative ADC measurements in differentiating glioma recurrence from radiation necrosis, Journal of the Neurological Sciences, vol.351, issue.1-2, pp.65-71, 2015.
DOI : 10.1016/j.jns.2015.02.038

H. Zhang, L. Ma, Q. Wang, X. Zheng, C. Wu et al., Role of magnetic resonance spectroscopy for the differentiation of recurrent glioma from radiation necrosis: A systematic review and meta-analysis, European Journal of Radiology, vol.83, issue.12, pp.2181-2190, 2014.
DOI : 10.1016/j.ejrad.2014.09.018

E. Thompson, E. Dosa, D. Kraemer, and E. Neuwelt, Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab, Journal of Neuro-Oncology, vol.88, issue.2, 2011.
DOI : 10.1007/s11060-010-0397-0

F. Calabria and G. Cascini, Current status of 18F-DOPA PET imaging in the detection of brain tumor recurrence, Hell J Nucl Med, 2015.

R. Youland, G. Kitange, T. Peterson, D. Pafundi, J. Ramiscal et al., The role of LAT1 in 18F-DOPA uptake in malignant gliomas, Journal of Neuro-Oncology, vol.101, issue.1, pp.11-19, 2013.
DOI : 10.1007/s11060-012-0986-1

P. Wiriyasermkul and S. Nagamori, Transport of 3-Fluoro-L-??-Methyl-Tyrosine by Tumor-Upregulated L-Type Amino Acid Transporter 1: A Cause of the Tumor Uptake in PET, Journal of Nuclear Medicine, vol.53, issue.8, pp.1253-61, 2012.
DOI : 10.2967/jnumed.112.103069

C. Papin-michault, Etude de l'expression de LAT1 dans les métastases cérébrales.Human health and Pathology, 2013.

J. Darcourt and M. Dufour, 18F-DOPA PET for the diagnosis of brain tumor recurrence: Correlation to LAT 1 expression, J Nuclear Med, vol.55, p.1889, 2014.

R. Young, A. Gupta, A. Shah, J. Graber, T. Chan et al., MRI perfusion in determining pseudoprogression in patients with gliobastoma